Combined Factor Xa and platelet inhibition to prevent recurrent events after ACS: the story so far

Chairperson: P. Gabriel STEG


To understand the dual-pathway strategy for secondary prevention after ACS
To learn about the value of adding rivaroxaban in addition to dual antiplatelet for secondary prevention after ACS
To gain insight into the increasing breadth of oral anticoagulant use in cardiology: the rivaroxaban profile


Session objectives

P.G. Steg

The ‘dual antithrombotic pathway’ strategy for ACS secondary prevention: rationale and data

D. Westermann

The added value of Factor Xa inhibition in practice: optimising management of complex ACS cases

A. Kastrati

The rivaroxaban clinical trial programme: proven experience and new directions in cardiology

G. Montalescot


More from Bayer Healthcare Pharmaceuticals

Visit website